Importance of neutralizing antibody positivity in Tur-kish multiple sclerosis patients
Derya Kaya, Serap Tufan, Serkan Özakbaş, Hakki Bahar, Emel Ada, Egemen İdiman
Department of Microbiology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Department of Neurology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Department of Neurology, Ordu Public Hospital, Ordu, Turkey;.
Department of Radiology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Neuroimmunology Laboratory, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
Neuroimmunology Laboratory, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey 3Department of Neurology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey Department of Neurology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey.
DOI: 10.4236/health.2013.511259   PDF   HTML     3,034 Downloads   4,250 Views  


The frequency and the consequences of binding and neutralizing antibodies (BAbs and NAbs) against Interferon beta (IFNbeta) in Turkish multiple sclerosis (MS) patients have not been determined yet, which could differ in such a country which is between Europa and Asia. The aim of the study is to assess the frequency of these antibodies, and to evaluate the impact of NAbs, from the clinical and radiologic aspects in Turkish patients with MS. One hundred and two MS patients were included. BAbs were screened using capture enzyme-linked immunosorbent assay (cELISA), and NAbs were detected via Myxovirus protein A (MxA) messenger RNA (mRNA) induction assay (real-time polymerase chain reaction-PCR) at the beginning and one year later. Relapse rate and expanded disability status scale (EDSS) were used to assess the clinical impact. Gadolinium enhanced lesions and T2 lesion volume were used as magnetic resonance imaging (MRI) parameters. Persistent NAb positivity defines to be positive both at first and then one year later. NAbs were detected in 12.2% (6/49) of IFNbeta-1b treated patients, and in 7.5% (3/40) of IFNbeta-1a SC treated patients, but none of the IFNbeta-1a IM treated patients had detectable NAbs. It was found that the mean relapse rate difference was significantly higher in persistent NAb negative patients (p = 0.024). Persistent NAb positivity had no effect on T2 lesion volume and contrast enhancing lesions. 60% of the persistent NAb positive patients had at least one relapse during one-year of follow-up. On the other hand, 32% of persistent NAb negative patients were detected to have at least one relapse. Data from this study suggest that patients may become unresponsive to IFNbeta therapy even when the frequency of NAbs does not prove to be as high as those in the literature. Nevertheless, one should keep in mind that disease activity is not always equal to NAb positivity.



Share and Cite:

Kaya, D. , Tufan, S. , Özakbaş, S. , Bahar, H. , Ada, E. and İdiman, E. (2013) Importance of neutralizing antibody positivity in Tur-kish multiple sclerosis patients. Health, 5, 1917-1923. doi: 10.4236/health.2013.511259.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Chou Bellomi, F., Scagnolari, C., Tomassini, V., Gasperini, C., Paolillo, A. and Pozzilli, C. (2003) Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. Journal of Neurological Sciences, 215, 3-8.
[2] Deisenhammer, F., Schellekens, H. and Bertolotto, A. (2004) Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis. Journal of Neurology, 215, 1131-1139.
[3] Bendtzen, K. (2003) Anti-IFN BAb and NAb antibodies: A minireview. Neurology, 61, 6-10.
[4] Sato, D.K., Nakashima, I., Fukazawa, T., Shimizu, Y., Tomizawa, Y. and Yokoyama, K. (2012) Neutralizing antibodies are associated with a reduction of interferon-β efficacy during the treatment of Japanese multiple sclerosis patients. The Tohoku Journal of Experimental Medicine, 228, 85-92.
[5] McDonald, W.I., Compston, A., Edan, G., Goodkin, D., Hartung, H.P. and Lublin, F.D. (2001) Recommended diagnostic criteria for MS: Guidelines from the international panel on the diagnosis of MS. Annuals of Neurology, 50, 121-127.
[6] Kurtzke, J.F. (1983) Rating neurologic impairment in multiple sclerosis: An expanded status scale (EDSS). Neurology, 33, 1444-1452.
[7] Polman, C.H., Kappos, L., White, R., Dahlke, F., Beckmann, K. and Pozzilli, C. (2003) European study group in interferon beta-1b in secondary progressive MS: Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology, 60, 37-43.
[8] Kappos, L., Clanet, M., Sandberg-Wollheim, M., Radue, E.W., Hartung, H.P. and Hohlfeld, R. (2005) Neutralizing antibodies and efficacy of interferon β-1a: A 4-year controlled study. Neurology, 65, 40-47.
[9] Perini, P., Clabrese, M., Biasi, G. and Gallo, P. (2004) The clinical impact of interferon beta antibodies in relapsing-remitting MS. Journal of Neurology, 251, 305-309.
[10] Kivisakk, P., Alm, G.V., Tian, W.Z., Matusevicius, D., Fredrikson, S. and Link, H. (1997) Neutralizing and binding anti-interferon-β-1b (IFN-β-1b) antibodies during IFN-β-1b treatment of multiple sclerosis. Multiple Sclerosis, 3, 184-190.
[11] Sorensen, P.S., Ross, C., Clemmesen, K.M., Bendtzen, K., Frederiksen, J.L. and Jensen, K. (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet, 362, 1184-1191.
[12] PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind plasebo controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet, 352, 1498-1504.
[13] IFNβ Multiple Sclerosis Study Group, University of British Colombia MS/MRI Analysis Group (1996) Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: Experience during the first three years. Neurology, 47, 889-894.
[14] Pachner, A.R., Cadavid, D., Wolansky, L. and Skurnick, J. (2009) Effect of anti-IFNβ antibodies on MRI lesions of MS patients in the BECOME study. Neurology, 73, 1485-1492.
[15] Pachner, A.R., Dail, D., Pak, E. and Narayan, K. (2005) The importance of measuring IFNbeta bioactivity: Monitoring in MS patients and the effect of anti-IFNbeta antibodies. Journal of Neuroimmunology, 166, 180-188.
[16] Aarskog, N.K., Maroy, T., Myhr, K.M. and Vedeler, C.A. (2009) Antibodies against interferon-beta in multiple sclerosis. Journal of Neuroimmunology, 212, 148-150.
[17] Sorensen, P.S., Koch-Henriksen, N., Ross, C., Clemmesen, K.M. and Bendtzen K. (2005) Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology, 65, 33-39.
[18] Malucchi, S., Sala, A. and Gilli, F. (2004) Neutralizing antibodies reduce the efficacy of IFN during treatment of multiple sclerosis. Neurology, 62, 2031-2037.
[19] Bertolotto, A., Malucchi, S., Sala, A., Orefice, G., Carrieri, P.B. and Capobianco, M. (2002) Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis. A follow up study in an independent laboratory. Journal of Neurology Neurosurgery Psychiatry, 73, 148-153.
[20] Hartung, H.P., Munschauer, F. and Schellekens, H. (2005) Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: Expert opinions based on the proceedings of an international consensus conference. European Journal of Neurology, 12, 588-601.
[21] Polman, C.H., Bertolotto, A., Deisenhammer, F., Giovannoni, G., Hartung, H.P. and Hemmer, B. (2010) Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurology, 9, 740-750.
[22] Sorensen, P.S., Koch-Henriksen, N. and Bendtzen, K. (2007) Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis? Multiple Sclerosis, 13, 616-621.
[23] Pungor Jr., E., Files, J.G., Gabe, J.D., Do, L.T., Foley, W.P. and Gray, J.L. (1998) A novel bioassay for the determination of neutralizing antibodies to IFN-β1b. Journal of Interferon Cytokine Research, 18, 1025-1030.
[24] Farrell, R., Kapoor, R., Leary, S., Rudge, P., Thompson, A. and Miller, D. (2008) Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Multiple Sclerosis, 14, 212-218.
[25] Lam, R., Farrell, R., Aziz, T., Gibbs, E., Giovannoni, G. and Grossberg, S. (2008) Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFNbeta in multiple sclerosis patients. Journal of Immunological Methods, 336, 113-118.
[26] Cludts, I., Meager, A., Thorpe, R. and Wadhwa, M. (2013) Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples. Journal of Immunological Methods, 395, 37-44.
[27] Bertolotto, A., Gilli, F., Sala, A., Capobianco, M., Malucchi, S. and Milano, E. (2003) Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology, 60, 634-639.
[28] Hesse, D., Sellebjerg, F. and Sorensen, S.P. (2009) Absence of MxA induction by interferon in patients with MS reflects complete loss of bioactivity. Neurology, 73, 372-377.
[29] Malucchi, S., Gilli, F., Caldano, M., Sala, A., Capobianco, M. and Di Sapio, A. (2011) One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients. Journal of Neurology, 258, 895-903.
[30] Pachner, A.R., Brady, J., Steiner, I. and Narayan, K. (2008) Management of neutralizing antibodies against beta-IFN in beta-IFN-treated multiple sclerosis patients. Journal of Neurology, 255, 1815-1817.
[31] Gilli, F., Marnetto, F., Caldano, M., Valentino, P., Granieri, L. and Di Sapio, A. (2007). Anti-interferon-beta neutralising activity is not entirely mediated by antibodies. Journal of Neuroimmunology, 192, 198-205.
[32] Pachner, A.R., Bertolotto, A. and Deisenhammer, F. (2003) Measurement of MxA mRNA or protein as a biomarker of IFN[beta] bioactivity: Detection of antibody-mediated decreased bioactivity (ADB). Neurology, 61, 24-26.
[33] Bertolotto, A., Gilli, F. and Sala, A. (2001) Evaluation of bioavailability of three types of IFNb in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification. Journal of Immunological Methods, 256, 141-152.
[34] Bertolotto, A., Sala, A., Caldano, M., Capobianco, M., Malucchi, S. and Marnetto, F. (2007) Development and validation of a real time PCR-based bioassay for quantification of neutralizing antibodies against human interferon-beta. Journal of Immunological Methods, 321, 19-31.
[35] Gilli, F., Marnetto, F., Stefanuto, G., Rinaldi, V., Farinazzo, F. and Malucchi, S. (2004) Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis. Journal of Molecular Diagnosis, 8, 185-194.
[36] Jensen, P.E.H., Sellebjerg, F., Sondergaard, H.B. and Sorensen, P.S. (2012) Correlation between anti-interferon-b binding and neutralizing antibodies in interferon-b-treated multiple sclerosis patients. European Journal of Neurolology, 19, 1311-1317.
[37] Sorensen, P.S. (2012) Effects of neutralizing antibodies to interferon beta in multiple sclerosis: A logical paradox. Multiple Sclerosis, 18, 131-132.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.